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Highlights 
 A systematic review of developed and/or validated a predictive model for MS. 
 Despite finding more than 6,000 studies, 15 articles were retained. 
 An over-interpretation of association in terms of prediction in the MS literature. 
 A need to integrate good standards in developing and validating predictive models. 
 Validated predictive tools for MS management are currently lacking. 
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Abstract  
 
Background. One of the main challenges in multiple sclerosis (MS) is to predict disease progression 
based on patient characteristics and therapeutic strategies. We therefore performed a systematic 
review to critically appraise the composite tools available for this purpose. 
Methods. We performed electronic database searches in MEDLINE, EMBASE, Web of Science and the 
Cochrane Library. We included studies in English or French that developed and/or validated a 
predictive model for MS patients. Two reviewers independently screened articles by title and 
abstract. Three teams of two reviewers assessed the full text of each relevant study. 
Results. Database searches yielded 6,035 studies after deduplication. Among the 42 screened full 
texts, 15 articles satisfied the eligibility criteria. Of these, six articles examined the development of 
predictive tools, six articles aimed to validate existing tools and three articles proposed both 
development and validation. We identified numerous methodological pitfalls, especially the lack of 
adequate validations in terms of discrimination and calibration. Only two scoring systems were 
externally validated several times: the Rio and the modified Rio scores. Nevertheless, their accuracies 
were highly variable, ranging from 65% to 91%. 
Conclusions. Overall, there is a lack of validated predictive tools in MS, and further external 
validation of the existing ones are required. Demonstration of the clinical usefulness is also needed 
prior to being transferred into clinical practice. Finally, our study illustrates that the MS literature 
needs to integrate good standards in developing and validating predictive models. 
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1. Introduction 
Multiple sclerosis (MS) is an inflammatory disease that affects the central nervous system. It is the 
leading cause of non-traumatic neurologic disability in young adults in the USA and Europe (1). MS is 
a heterogeneous disease with important variability between patients in terms of natural history (2), 
and this variability is even greater due to the large number of disease-modifying therapies (DMT) (3). 
However, the expected evolution of the disease, with or without DMT, is essential for guiding 
informed decisions about initiation, switching, or even cessation of DMT. 
One of the main challenges is to predict disease progression based on the patients’ characteristics 
and the therapeutic strategies. In the current era of precision medicine, where genetic and biological 
parameters may be associated with the disease evolution and the treatment response, this may 
result in important advances in MS patient treatment. Early identification of suboptimal responder 
patients could for instance prevent both acute inflammatory injury and the neurodegenerative 
processes leading to irreversible disabilities and secondary progressive forms. The first and probably 
most well-known tentative is the Rio scoring system (4), which aims to predict the response to 
interferon beta (IFN-) therapy at 1-year post-initiation. 
Besides medical decision making, being able to inform patients about their likely disease progression 
is important. Similar to other chronic diseases, anxiety is a daily concern for MS patients, with a 
prevalence ranging from 14% to 34% (5). The possible consequences are a reduction in quality of life 
(6), treatment non-compliance (7), or even exacerbation of disease symptoms (8). For some patients, 
anxiety is partially due to the absence of information regarding the future of their disease (6). Many 
patients need better quality information than they initially received. Seventy-five percent of patients 
reported inadequacies in information they had been offered about MS (9). Besides limiting anxiety, 
informing a patient of her/his prognosis and corresponding treatment options is of primary 
importance in a patient-centered vision of care, as this allows joint decisions on further treatments 
to be made by the patient and neurologist. 
The aim of this systematic review is to critically appraise the composite tools available in MS to 
predict disease evolution. The specific objectives were to identify relevant risk prediction models, to 
describe the methods used for their development, to investigate their validation, and to discuss their 
clinical utility. 
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2. Methods 
2.1. Search strategy 
This systematic review was performed according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (10). The literature search strategies were 
developed using Medical Subject Headings (MeSH) terms and keywords related to multiple sclerosis, 
predictive models and validation studies (Table 1). We performed electronic database searches in 
MEDLINE, EMBASE, Web of Science and the Cochrane Library. We also explored the references of the 
selected articles by using Google Scholar. All sources were reviewed up to the 30th of November 
2017. 
 
2.2. Study selection 
Two reviewers independently screened articles by title and abstract. Three teams of two reviewers 
assessed the full text of each potentially relevant study. Where disagreements occurred, the final 
decision was based on a discussion with another independent reviewer. 
We included studies in English or French that developed and/or validated a predictive model for MS. 
We excluded non-human studies, studies with no original statistics (review articles, reports of 
registries), studies that did not deal with multiple sclerosis (such as clinically isolated syndrome), 
medical-economic studies, association studies, studies aiming to develop new methods with no 
clinical objective, studies which developed or validated non-predictive scores/scales (such as patient 
reported outcomes), descriptive studies, diagnostic studies, studies with a predictive outcome not 
related to the disease evolution, and studies where neither the full text nor the summary was 
available. 
We extracted the data using the CHeck list for critical Appraisal and data extraction for systematic 
Reviews of prediction Modelling Studies (CHARMS) (11). 
 
3. Results 
3.1. Description of the selected studies 
As detailed in Figure 1, we identified 6,035 unique articles, among which 5,993 were excluded based 
on titles and abstracts. Among the 42 screened full texts, 15 articles (4,12–25) that respected the 
eligibility criteria were included, and all of these dealt with relapsing-remitting MS. Of these, six 
articles examined the development of prediction tools (4,14–16,19,25), six articles aimed to validate 
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existing tools (12,20–24), and three articles proposed both development and validation (13,17,18). 
Seven articles were based on patients treated by IFN- only, three by several treatments, one by 
teriflunomide only, one by fingolimod only and two articles included untreated patients. One 
manuscript did not report information on treatment. The repartition in terms of geography was six 
from Italy, three from Spain, one from Korea, one from Canada, one from Israel and six from several 
countries (international studies). In terms of study design, nine articles were based on observational 
data and five on clinical trials. All articles were published in Neurology journals, except one in 
multidisciplinary sciences and one in Immunology. The publication year ranged from 1996 to 2017. 
Seven articles (46.7%) were published since 2013. 
 
3.2. Description of the predictive tools 
As illustrated in Table 2, nine predictive tools were identified. The Rio score (4), the modified Rio 
score (13) and the MAGNIMS score (14) were computed at 1-year post IFN- prescription for 
predicting the suboptimal response to treatment. These three scoring systems aimed to help the 
decision for an early switch from IFN- to second-line therapy for high-risk patients. The Rio score 
was calculated by using relapse occurrence, Magnetic Resonance Imaging (MRI) activity and EDSS 
(Expanded Disability Status Scale) progression. In contrast, the modified Rio score (13) and the 
MAGNIMS score (14) were only based on MRI activity and EDSS progression. The development of the 
Rio score (4) also differed from the two other scores by ignoring the treatment switch due to lack of 
efficacy in the definition of the suboptimal response. 
The BREMS score (15), the BREMSO score (16) and the tool proposed by Calabrese et al. (17) aimed 
to predict early onset of the secondary progressive phase. The first score was based on demographic 
and clinical variables collected during the first-year post-disease onset, while the second score only 
used data available at disease onset. The authors proposed to use it in observational studies for 
reducing confounders. The third tool (17) was proposed with no landmark time, i.e. it can be 
computed at any time of the disease course. 
The three other scoring systems (18,19,25) were also proposed with no landmark time. While one 
can expect that these tools with no landmark should include the disease duration among their 
predictive variables as a proxy of the disease history, only the model proposed by Weinshenker et al. 
(19) considered this parameter for predicting the time-to-EDSS 6. Sormani et al. (18) aimed to predict 
the risk of relapse, while Achiron et al. (25) aimed to predict the neurological disability (a composite 
outcome from EDSS evolution and relapse occurrence). Among the three tools, only Sormani et al. 
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(18) proposed a possible utility for identifying MS patients with a high risk of relapse as inclusion 
criteria in clinical trials. 
 
3.3. Developments: predictive variable selection and modeling 
Among the 15 selected articles, nine predictive tools were developed. Six tools were proposed with a 
statistical selection of the predictive variables (15–19,25), the three others (4,13,14) being scoring 
systems a priori defined by experts. Among the six articles, the following statistical approaches were 
used: Markov chain Monte Carlo Bayesian model (15,16), Support Vector Machine (25), logistic 
model (17,19) and Cox model (18). Figure 2 presents the distribution of the predictive variables 
included in the nine predictive tools. The most frequent variables were number of new T2 lesions and 
relapses. EDSS and age were used in three models. Other predictors less commonly used were 
gender, duration of the disease, sphincter onset, pure motor onset, moto-sensory onset, sequelae 
after onset, neurological functional systems, cerebellar cortical volume and cortical lesion volume. 
The predictive model proposed by Achiron et al. (25) was based on 34 genes with no MRI or other 
clinical parameters. Importantly, treatments were not included in any model. 
 
3.4. Methodological pitfalls in estimating apparent prognostic capacities 
As reported in Table 2, the apparent prognostic capacities (estimated from the learning sample) were 
never compared with other existing prognostic tools. This issue may be because each tool aimed to 
predict different outcomes or the same outcome with different definitions. When the apparent 
prognostic capacities are reported in mid- or long-term studies, the corresponding statistical analyses 
did not appropriately deal with such a time-dependent context. More precisely, while Cox 
regressions were used for the developments based on right-censored data, it was ignored in 
estimating the corresponding prognostic capacities by excluding patients with not enough follow-up: 
indicators such as sensitivity (SE) and specificity (SP) were naively estimated by the corresponding 
proportions. 
 
3.5. External validations 
Three articles (13,17,18) proposed both the development and external validation of a predictive tool. 
In addition, we identified six studies (12,20–24) with only external validation of previously developed 
models. Among these nine articles, five proposed a validation of the modified Rio score (13), with 
accuracies ranging from 65% to 91%. Except in the study by Lattanzi et al. (22) due to small sample 
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size, the four other articles proposed the same stratification into two groups (score 0-1 versus 2-3) 
and reported SE from 19% to 96%, SP from 72% to 97%, PPV from 28% to 86% and NPV from 68% to 
93%. 
Three articles (12,21,23) proposed a validation of the Rio score (4). The accuracies ranged from 62% 
to 93%. The same stratification (0-1 versus 2-3) resulted in SE ranging from 45% to 98%, SP from 67% 
to 86%, PPV from 43% to 92% and NPV from 85% to 93%. 
One article (20) aimed to validate the predictive capacities of the MAGNIMS score (14), reporting an 
accuracy of 63%. Other indicators were estimated (SE, SP, PPV and NPV), but the corresponding 
stratification was not based on the MAGNIMS score alone and was difficult to understand. 
Bergamashi et al. (24) proposed a validation of the BREMS score (15). Nevertheless, they did not 
report the accuracy, and the stratification was proposed with irrelevant extreme cuts-offs by using 
extreme values (5th and 95th percentiles). Sormani et al. (18) proposed both the development and 
external validation in the same article, but the discriminative capacities were not reported. Calabrese 
et al. (17) also proposed both the development and external validation. The accuracy equaled 92%, 
but no rule was reported for the stratification. 
 
3.6. Methodological pitfalls in external validations 
No study precisely reported the calibration, for instance, by plotting observed versus predicted 
probabilities of events. As for the apparent prognostic capacities, the studies mainly reported 
accuracy, SE, SP, PPV and NPV; but no study considered the right-censoring in the corresponding 
estimation when necessary. Even more worrisome, the dispersion of these indicators was not 
reported: we have no idea of the corresponding standard errors or confidence intervals. This is even 
more important regarding the high range of these values for each scoring system and the small 
sample sizes of three studies (17,22,23). 
 
4. Discussion 
In MS management, the individual evaluation of the expected evolution of disease is important. In 
order to identify predictive tools potentially useful in clinical practice, we decided to perform this 
review, including an exhaustive research, a careful selection of studies, and a double-blind data 
extraction. 
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Despite finding more than 6,000 studies related to prediction in MS, we retained only 15 articles that 
were aimed at developing composite predictive tools and/or validating their capacities. One of the 
main reasons was the over-interpretation of association in terms of prediction (Figure 1). It occurred 
in 2,880 (47.8%) articles (2,217 association/impact studies and 669 studies for evaluating efficacy or 
safety of drugs). It is quite common to find that factors, defined by authors as prognostic and/or 
predictive, are in fact only correlated with the outcome. Indeed, the magnitude of odds-ratios (27) or 
hazard-ratios (28) do not inform on prognostic capacities. Nevertheless, it can lead to 
misinterpretations concerning the clinical utility of the marker (26). 
According to our results, only two scoring systems were externally validated several times: the Rio 
score (4) and the modified Rio score (13). Compared to the other predictive tools, one can highlight 
their possible clinical utility by identifying in patients treated by IFN- for 1 year a stratum at high risk 
of disability progression, who may benefit from an early switch to second line therapy. Nevertheless, 
to our knowledge, no study was performed to demonstrate such usefulness. 
Our results also highlight that further external validation of the Rio score (4) and the modified Rio 
score (13) must be performed using large samples and well-validated statistical methods adapted to 
time-to-event data. Importantly, both calibration and discrimination must be evaluated. Firstly, the 
calibration aims to evaluate the concordance between observed and predicted probabilities of 
events. It can be graphically evaluated or statistics can be computed, such as the Hosmer-Lemeshow 
test (27). Secondly, the discrimination aims to evaluate the separation between individuals who will 
present events from patients who will not. For instance, indicators such as area under ROC curves 
(AUC), SE and SP can be used. Importantly, bootstrapping can be used to obtain the corresponding 
confidence intervals, which were never reported in the articles included in our review. 
When necessary for long-term studies, both the calibration and the discrimination analyses must 
consider right-censoring. For discrimination analyses, Heagerty et al. (28) proposed an estimator of 
ROC curves in the presence of such incomplete data. The Kaplan-Meier estimator (29) can be used to 
estimate the observed probabilities in calibration analyses. In contrast, our review highlights the 
omission of right-censoring in the estimation of prognostic capacities. It consists of removing patients 
with insufficient follow-up, such a naïve approach being potentially associated with bias and higher 
variance (30). 
One might assume that both the Rio and modified Rio scores may be enriched by other parameters 
in order to increase their discriminative capacities, as proposed by Sormani et al. (18) One can first 
study the parameters retained in the other predictive tools, such as age, gender and EDSS (Figure 2). 
Another limitation of the two scoring systems is the lack of update after 1-year post INF- initiation. 
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The occurrence of relapse, new MRI results, or EDSS evolution may be useful to compute dynamic 
predictions and to improve the two time-fixed scoring systems. Recent developments in joint models 
for longitudinal markers and time-to-event may offer an interesting framework (31,32). In relation to 
this, our review underlines the importance of avoiding previously identified methodological pitfalls: 
multiplication of outcomes, different definitions of the same outcome, lack of internal and external 
validation, poor consideration of incomplete data and small sample size. 
 
5. Conclusions 
Validated and clinically useful predictive tools for MS management are currently lacking. Whilst the 
Rio score (4) and the modified Rio score (13) are the only tools with several external validations, 
further studies using well-performed external validation and usefulness demonstrations are needed 
to encourage and justify their use in clinical practice. Our study also demonstrates that the MS 
literature needs to establish a consensus on the definition, development and validation of predictive 
models. 
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8. Tables 
 
 
Table 1: Database search strategy 
 
Theme Terms used Position 
Multiple Sclerosis 
(“multiple sclerosis” OR “disseminated sclerosis”) 
AND 
MeSH Terms, 
Title, Abstract, 
Keyword 
Prediction 
(“predictive value of tests” OR “prediction” OR “predict” OR “predicts” OR 
“predictive” OR “predicting” OR “predicted” OR “probability” OR 
“prognosis” OR “prognostication” OR “prognosticate” OR 
“prognosticates” OR “prognostic” OR “precision medicine” OR “stratified” 
OR “precision” OR “personalized” OR “personalized” OR “risk 
assessment” OR “risk”) 
AND 
MeSH Terms, 
Title, Abstract, 
Keyword 
Modelling 
(“models, statistical” OR “model” OR “models” OR “modeling” OR 
“modelling” OR “equation” OR “equations” OR “regression” OR 
“algorithm” OR “algorithms” OR “score” OR “scores” OR “scoring” OR 
“nomograms” OR “nomogram”) 
AND 
MeSH Terms, 
Title, Abstract, 
Keyword 
Validation 
(“prediction” OR “predict” OR “predicts” OR “predictive” OR “predicting” 
OR “predicted” OR “validation studies as topic” OR “validation” OR 
“validity” OR “validate” OR “validates” OR “validated” OR “calibration” 
OR “discrimination” OR “classification” OR “bootstrapping” OR “cross-
validation” OR “C-statistic” OR “C-index” OR “ROC curve” OR “ROC” OR 
“area under curve” OR “AUC” OR “area under curve”) 
MeSH Terms, 
Title, Abstract, 
Keyword 
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Table 2: Description of the manuscripts related to the Rio and Modified Rio scores. 
 
 
 
THE RIO SCORE (RS)  
Rio at al.(4) 
THE MODIFIED RIO SCORE (MRS) 
Sormani et al.(13) 
D
EV
EL
O
P
M
EN
T
 
inclusion criteria 
Prospective cohort 2003-2006, RRMS treated with IFN-, available MRI 12 months 
after onset treatment 
RRMS treated with IFN-, more than one year of follow-up 
design, size prospective cohort, n=222 clinical trial, n=365 
outcome 
treatment failure at 24 months defined by relapse or confirmed disease progression, 
the latter being defined by EDSS progression > 1 point sustained over at least 6 months 
and confirmed at the end of the follow-up 
time to treatment failure defined by the presence of relapse or confirmed disease progression, the latter being defined by EDSS progression > 1 point 
when J0 < 6 or progression > 0.5 point when J0 > 6 sustained over at least 6 months or switch to other therapies for lack of efficacy 
landmark time 12 months after starting treatment  12 months after starting treatment  
predictors relapse, EDSS, active lesions relapse, new T2 lesions 
tool 
construction 
arbitrary classification evaluated by a logistic model arbitrary classification evaluated by Cox model 
utility 
to select potential candidates to receive alternative therapeutic approaches that may 
work better than IFN- 
to select potential candidates to receive alternative therapeutic approaches that may work better than IFN- 
limits 
confusion between correlation and prediction 
 
no internal or external validation 
no comparison with the previous Rio Score (4) 
 
no consideration of the right-censoring in the study of prognostic capacities 
EX
T
ER
N
A
L 
V
A
LI
D
A
TI
O
N
 
 
Romeo et al.(12) Hyun et al.(23) Rio et al.(21) Sormani et al.(13) Romeo et al.(12) Hyun et al.(23) Lattanzi et al.(22) Rio et al.(21) 
sample prospective cohort, n=368 
retrospective cohort, 
n=70 
prospective cohort, 
n=233 
cohort, n=222 prospective cohort, n=390 retrospective cohort, n=70 retrospective cohort, n=24 
prospective cohort, 
n=233 
differences in 
outcome 
definition 
disability 1: as in Rio (4) 
 
disability 2: EDSS progression > 1.5 
points when J0 < 2.5 and 1 point 
when J0 in 2.5-5.5 sustained over 
at least 6 months and confirmed 
at the end of the follow-up 
disability: EDSS 
progression > 1 point 
when J0 < 6 and 0.5 
point when J0 > 6 during 
the ensuring 2 years of 
IFN- 
not clearly defined: 
probably the first 
event between 
reaching EDSS at 7.5 
or secondary 
progressive phase 
 
disability 1 as in Rio (4) 
 
disability 2: EDSS progression > 1.5 
points when J0 < 2.5 and 1 point 
when J0 in 2.5-5.5 sustained over 
at least 6 months and confirmed 
at the end of the follow-up 
disability: EDSS progression > 
1 points when J0 < 6 and 0.5 
point when J0 > 6 during the 
ensuring 2 years of IFN- 
disability: same as in Sormani et 
al. (13), but with a cut-off of 
EDDS at J0 at 5 instead 6 
not clearly defined: 
probably the first 
event between 
reaching EDSS at 7.5 
or secondary 
progressive phase 
global 
performance 
accuracy = 62% (disability 1) and 
65% (disability 2) 
accuracy = 93% accuracy = 77% accuracy = 69% 
accuracy = 65% (disability 1) and 
69% (disability 2) 
accuracy = 91% accuracy = 79% accuracy = 74% 
prognostic 
capacities 
binary test: 0-1 versus 2-3 
 
SE = 45% (disability 1) and 54% 
(disability 2) 
 
SP = 67% (disability 1) and 68% 
(disability 2) 
binary test: 0-1 versus 2-
3 
 
SE = 98%, SP = 75% 
 
PPV=92%, VPN=93% 
binary test: 0-1 versus 
2-3 
 
SE = 40%, SP = 86%, 
PPV = 43%, NPV = 
85% 
binary test: 0-1 
versus 2-3 
 
SE = 24%, SP = 97% 
 
PPV = 83%, NPV = 
68% 
binary test: 0-1 versus 2-3 
 
SE = 42% (disability 1) and 51% 
(disability 2) 
 
SP = 72% (disability 1) and 72% 
(disability 2) 
binary test: 0-1 versus 2-3 
 
SE = 96%, SP = 75%  
 
PPV=86%, VPN=93% 
binary test: 0-2 versus 3 
 
SE = 50%, SP = 94% 
 
PPV = 80%, NPV = 79% 
binary test: 0-1 versus 
2-3 
 
SE = 19%, SP = 88%, 
PPV = 29%, NPV = 
81% 
limits/remark 
no consideration of the right-
censoring in prognostic capacities 
 
no calibration 
 
no PPV/NPV but can be obtained 
from survival curves 
 
small sample size 
 
no consideration of the 
right-censoring in 
prognostic capacities 
 
no calibration 
 
uncomprehensive 
analyses in low-risk and 
high-risk subgroups 
the landmark time is 
not clearly defined (1- 
or 2-years post-
treatment) 
 
no consideration of 
the right-censoring 
limits listed above 
 
the decision rule 
changes for 
validation 
 
poorly performed 
calibration 
no PPV/NPV but can be obtained 
from survival curves 
 
no consideration of the right-
censoring in prognostic capacities 
 
no calibration 
small sample size 
 
no consideration of the right-
censoring in prognostic 
capacities 
 
no calibration 
 
irrelevant analyses in low- 
and high-risk subgroups 
small sample size 
 
no consideration of the right-
censoring in prognostic 
capacities 
 
binary test with a different cut-
off 
 
patients treated by Fingolimod 
(different landmark) 
no consideration of 
the right-censoring 
 
the landmark time is 
not clearly defined (1- 
or 2-years post-
treatment) 
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Table 2 (continued): Description of the manuscripts related to the MAGNIMS, the BREMS and the BREMSO scores. 
 
 
 
THE MAGNIMS SCORE  
Sormani et al.(14) 
THE BREMS SCORE  
Bergamashi et al.(15) 
THE BREMSO SCORE  
Bergamashi et al.(16)  
D
EV
EL
O
P
M
EN
T
 
inclusion criteria 
RRMS treated with IFN- as their first therapy, assessments of EDSS score, 
number of relapses and T2 lesions at therapy initiation and after 1 year, at 
least yearly clinical assessments, including EDSS score and number of 
relapses, for a minimum of 2 additional years 
RRMS with disease duration ≥ 3 years, time between symptoms onset and first 
examination ≤ 12 months 
RRMS patients (2001 McDonald's criteria) 
sample clinical trial, n=1280 prospective cohort, n=186 prospective cohort, n=14211 
outcome 
time to treatment failure defined by the presence of relapses or confirmed 
disease progression, the latter being defined by EDSS progression > 1 point 
when J0 < 6 or progression > 0.5 point when J0 > 6 or > 1.5 points when J0=0 
sustained over at least 6 months or switch for lack of efficacy 
time to onset of secondary progressive phase of the disease, defined by a 
persistent increase in at least one point in the EDSS level for 6 months 
time to onset of secondary progressive phase of the disease as defined in the 
BREMS study (15) or to major clinical disability (EDS > 6) 
landmark time 12 months after treatment start 12 months after onset of disease 12 months after onset of disease 
predictors relapse, new T2 lesions 
age, sex, sphincter onset, pure motor onset, motor and sensory onset, number 
of neurological functional systems involved at onset, incomplete recovery after 
onset 
age, sex, sphincter onset, pure motor onset, motor and sensory onset, 
sequelae after onset, number of involved neurological functional systems at 
onset, number of sphincter plus motor relapses, EDSS ≥ 4 outside relapse 
methods Cox model Markov chain Monte Carlo Bayesian approach update of the previous model (15) 
utility 
to select potential candidates to receive alternative therapeutic approaches 
that may work better than IFN- 
inclusion criteria in clinical trial to select patients according to their expected 
disease course pattern  
 
surrogate endpoint in clinical trial 
stratification of patients with a similar expected evolution to reduce 
confounders due to the lack of randomization in observational studies 
limits 
small number of possible predictors 
 
no update of the score after 12 months 
 
no consideration of the right-censoring in the study of prognostic capacities 
 
different definition of the treatment failure compared the Rio score (4) and 
modified Rio score (13) 
 
no internal or external validation 
small sample size 
 
no update of the score after 12 months 
 
no estimation of the apparent prognostic capacities 
 
no validation 
no validation 
 
no update of the score after 12 months 
 
predicted outcome different from the initial BREMS study (15) 
 
no consideration of the right-censoring in the study of prognostic capacities 
EX
T
ER
N
A
L 
V
A
LI
D
A
TI
O
N
 
 
Sormani et al.(20) Bergamashi et al.(24) 
 
sample clinical trial, n=551 prospective cohort, n=1245 
 
differences in 
outcome definition 
the disability worsening with no definition same as previously (15), except a duration of 12 instead 6 months  
global performance  accuracy = 63% no 
 
prognostic capacities SE = 84%, SP = 24%, PPV = 67%, NPV = 45% 
binary test: BREMS < 5th percentile (value at 2) versus < 5th percentile: SP = 
100%, SE = 8%, PPV = 100%, NPV = 18% 
 
binary test: BREMS < 95th percentile (value at -0.63) versus > 95th percentile: 
SP = 99%, SE = 17%, PPV = 86%, NPV = 83% 
 
limits/remark 
no calibration 
 
patients treated by Teriflunomide (different landmark) 
 
the use of a different scoring system compared to the initial proposal (14) 
 
reclassification of patients after baseline according the initial proposal (14) 
no consideration of the right-censoring in prognostic capacities 
 
no calibration 
 
no relevance of the proposed extreme values of cut-off 
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Table 2 (continued): Description of the manuscripts related to the four other scores with no name. 
 
 
 Weinshenker et al.(19) Sormani et al.(18) Achiron et al.(25) Calabrese et al.(17) 
D
EV
EL
O
P
M
EN
T
 
inclusion criteria no precision 
RRMS diagnosis for at least 6 months, EDSS score of 0.0 to 
5.0, at least one documented relapse in the year before 
baseline, relapse-free and steroid free in the 30 days prior to 
baseline, complete clinical and MRI data at baseline, did not 
have to be treated with disease-modifying agents 
RRMS patients treated with IFN-, never received 
cytotoxic treatment, free of steroid treatment 
RRMS patients (McDonald criteria 2001), at least 5 years of 
disease duration 
sample prospective cohort, n=219 clinical trial, n=539 prospective cohort, n=19 prospective cohort, n=334 
outcome time to reach EDSS at 6 time to first relapse  
neurological disability (primary outcome) 
 
total number of relapses (secondary outcome) 
secondary progressive phase of the disease 
landmark time No no no No 
predictors 
Disease duration, EDSS, follow-up, 
progression index, other variables from a 
previous model 
previous 2 years relapse, numbers of enhancing lesions 34 genes age, cortical lesion volume, cerebellar cortical volume 
methods logistic model Cox model Support Vector Machine logistic model 
utility not defined 
definition of MS patients with high risk of relapse as inclusion 
criteria in clinical trials 
not defined not defined 
limits 
no validation 
 
the follow-up is included in the model 
(conditioning on future) 
no evaluation of the apparent discriminative capacities 
small sample size 
 
training and validation dataset not clearly defined 
 
internal validation strategy not clear 
 
removal of patients with an intermediate outcome 
(conditioning on future) 
 
no available equation/algorithm/rule 
no consideration of time-to-event in this mid-term study 
 
the high inter-observer and inter-center variability when 
heterogeneous scans 
 
the white matter variables were not analyzed 
EX
TE
R
N
A
L 
V
A
LI
D
A
TI
O
N
 
  
Sormani et al.(18) 
 
Calabrese et al.(17) 
sample 
 
clinical trial, n=117 
 
prospective cohort, n=83 
differences in 
outcome definition 
 no difference  no difference 
global performances 
 
no 
 
accuracy = 92% 
prognostic capacities 
 
binary test: score < 95th percentile versus < 5th percentile: 
predictive values can be obtained from the survival curves (up 
to PPV~85%, NPV~55%) 
 
SE = 84%, SP = 94% 
limits/remark 
 
identical than previously listed 
 
the calibration results were poor 
 
no evaluation of discriminative capacities 
 
small sample size 
 
no calibration  
 
no threshold definition for computing SE and SP 
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9. Figures 
Figure 1: Flowchart of the article selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The distribution of the predictors according to the number of tools based on these parameters 
 
Records identified 
through MedLine 
database (n=1794) 
Records identified 
through EMBASE 
database (n=4339) 
Records identified 
through Web of 
Science database 
(n=2552) 
Records identified 
through Cochrane 
Library database 
(n=585) 
Records screened after duplicates removed 
(n=6035) 
Full-text articles assessed for eligibility 
(n=42) 
Studies included (n =15) 
5993 articles excluded: 
- association/impact studies (2,217) 
- not only multiple sclerosis (1,262) 
- evaluation studies/efficacy, safety (669) 
- no human studies (436)  
- description of tools (312) 
- no original data/statistics (283) 
- quality of life/cost utility (218) 
- descriptive studies (104) 
- medical-economic studies (60) 
- diagnostic studies (59) 
- full-text not available (47) 
- outcome not related to MS evolution (45) 
- language (18) 
3235 duplicates excluded 
26 articles excluded: 
- correlation studies (4) 
- methodological studies (3) 
- association studies (2) 
- outcome not related to MS evolution (2) 
- no original data/statistics (2) 
- not only multiple sclerosis (2) 
- description or validation of scales (1) 
         
